In REDEFINE 1 (NEJM 2025, n=3,417, 68 weeks), cagrilintide monotherapy at 2.4 mg produced 11.8% mean body-weight reduction versus 2.3% with placebo
Liposomal or intravenous formulations may improve absorption, but clinical evidence in liver health remains limited
Compounding allows the active drug to be delivered in a hypoallergenic base free of the offending excipient
These might be a better option for people with increased nutrient needs or those at a greater risk of deficiency, including individuals with medical conditions that affect absorption
Theanine thng c bn di dng thc phm b sung dng vin nang hoc trong chit xut tr xanh
As of 2026, cagrilintide isnt available in the United States, and it isnt part of any FDA-approved medication